Strategic Advisors’s Pfizer PFE Stock Holding History

Strategic Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,000	Closed	-$26.5K	–	199
2024 Q4	$26.5K	Buy	+1,000	New	+$27.1K	﹤0.01%	197

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Strategic Advisors's PFE Position: Q2 2026 in Review

Strategic Advisors reduced its Pfizer (PFE) stake by 9.6% in Q2 2026, selling an estimated $50.6K and leaving 18,216 shares worth $439K. The position accounts for 0.1% of the portfolio, ranked #119.

Strategic Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.12M in Q1 2022. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Strategic Advisors held 18,216 shares of Pfizer worth $439K as of Q2 2026.
Strategic Advisors sold 1,935 Pfizer shares in Q2 2026, an estimated $50.6K.
Pfizer made up 0.1% of Strategic Advisors's portfolio in Q2 2026, its #119 holding.
Strategic Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
Strategic Advisors's Pfizer position peaked at $8.12M in Q1 2022.
2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Strategic Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.